Prevalence and Risk Factors of Dry Eye Disease
Laura Periman, MD, discusses the prevalence and risk factors of dry eye disease.
Source: hcplive.com
📰 Ocular Surface News
Page 3 - Ocular Surface News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ocular Surface. Real-time updates on events, politics, business and more.
Dry Eye Disease Overview
Ophthalmologist experts provide an overview of dry eye disease.
Source: hcplive.com
"Recombinant Human Clusterin Seals Damage to the Ocular Surface Barrier" by Shravan K. Chintala, Jinhong Pan et al.
There is a significant unmet need for therapeutics to treat ocular surface barrier damage, also called epitheliopathy, due to dry eye and related diseases. We recently reported that the natural tear glycoprotein CLU (clusterin), a molecular chaperone and matrix metalloproteinase inhibitor, seals and heals epitheliopathy in mice subjected to desiccating stress in a model of aqueous-deficient/evaporative dry eye. Here we investigated CLU sealing using a second model with features of ophthalmic pre...
Drug Administration Good Manufacturing Practices Dry Eye Atrix Metalloproteinase Inhibitor Olecular Chaperone Ocular Surface
Source: uow.edu.au
Bausch + Lomb Corporation: Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
NOV03 is Being Investigated to Treat the Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023 Bausch Lomb Corporation (NYSE/TSX:
Source: finanznachrichten.de
Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian
TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-0...
Source: pharmiweb.com
Finger-prick autologous blood eye drops for dry eye disease
Quantitative & qualitative efficacy of finger-prick autologous blood eye drops versus conventional medical therapy for the treatment of severe dry eye disease.
United Kingdom Eteläuomen Läi Owen Mumford Health Research Authority Tear Film Ocular Surface Society Tear Film
Source: dovepress.com
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
Aldeyra Therapeutics, Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for topical ocular reproxalap, an investigational new drug candidate,... | November 29, 2022
United States Ptoddc Brady Drug Administration Exchange Commission Aldeyra Therapeutics Inc Securities Exchange
Source: marketscreener.com
OKYO Pharma LTD: OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology bio-pharmaceutical
Tufts University United States Tufts Medical Center Pedram Hamrah Garys Jacob Tufts University School Of Medicine
Source: finanznachrichten.de
Investegate |OKYO Pharma LTD Announcements | OKYO Pharma LTD: OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
Investegate announcements from OKYO Pharma LTD, OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
Source: investegate.co.uk
OKYO Pharma Hosting Key Opinion Leader Event Introducing
Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO)...
Source: globenewswire.com